Whether an 80-year-old should take a statin depends almost entirely on one question: have they already had a heart attack, stroke, or been diagnosed with cardiovascular disease? For people who have, the evidence strongly favors continuing statin therapy. For those who haven’t, the picture is genuinely uncertain, and major guidelines disagree with one another on what to recommend. A landmark trial published in 2025 adds important clarity but still doesn’t settle the debate. The honest answer is that this is one of the more individualized decisions in medicine, and age alone is a poor way to make it.
The Critical Split Between Primary and Secondary Prevention
In cardiology, “secondary prevention” means you already have known cardiovascular disease and the goal is to prevent a second event. “Primary prevention” means you have no diagnosed disease and you’re trying to stop the first one from ever happening. This distinction matters enormously at age 80 because the strength of the evidence is completely different on each side.
For secondary prevention, the data are reassuring. A large meta-analysis pooling data from nine randomized trials of older adults with prior heart attacks or known artery disease found roughly a 22% reduction in death from any cause, a 30% reduction in death from coronary disease, and a 26% reduction in nonfatal heart attacks among statin users. The PROSPER trial, the first to specifically enroll older patients, found that pravastatin had a greater effect when used for secondary prevention than primary prevention. And a broader meta-analysis confirmed that the proportional risk reduction in older patients with known vascular disease was similar to what younger patients experience.1PubMed Central. Statin Therapy for Primary and Secondary Prevention in Older Adults
For primary prevention, the story is far less clear. A systematic review covering eight studies and over 436,000 participants found that most did not show a significant decrease in major cardiovascular events among adults over 80 who had no prior heart disease.2PubMed. Statins in Primary Prevention in People Over 80 Years One major problem is that people over 75 have been substantially underrepresented in randomized trials of statin therapy, so the evidence base is thinner than it should be for the age group that carries the highest absolute cardiovascular risk.3International Journal of Cardiology Cardiovascular Risk and Prevention. Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review
Not all the evidence tilts negative, though. A large retrospective cohort study of adults aged 80 and older found that statin use was associated with a 31% reduction in mortality and a 20% reduction in new coronary events over four years, with no significant increases in muscle disease, diabetes, or dementia. The catch: patients who had discontinued statins before turning 80 did not see these benefits.4PubMed Central. Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study Being a retrospective study rather than a randomized trial, it can’t prove causation, but the signal was strong enough to keep the conversation alive.
What the STAREE Trial Found
The biggest piece of new evidence comes from STAREE, a randomized controlled trial published in the New England Journal of Medicine in 2025. This trial enrolled community-dwelling older adults without cardiovascular disease and randomized them to atorvastatin 40 mg or placebo, with a median follow-up of about six years. The headline result: atorvastatin did lower the risk of major cardiovascular events compared to placebo. But it did not lead to longer disability-free survival. Death from any cause, dementia, or persistent physical disability occurred at similar rates in both groups.5PubMed. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
That distinction is important because for many older adults, the question is not simply “will I have fewer heart attacks?” but “will I live better and longer overall?” STAREE suggests statins prevent cardiac events even in healthy older people, but that preventing those events didn’t translate into more time spent alive and independent. A separate observational study of healthy adults over 70 reached a similar conclusion: statin use was associated with lower cardiovascular disease and physical disability risk, but not with disability-free survival, longer life, or lower dementia risk.6Journal of the American College of Cardiology. Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults
Another trial, PREVENTABLE, is still underway. It is comparing atorvastatin 40 mg against placebo in 20,000 community-dwelling adults aged 75 and older without cardiovascular disease, disability, or dementia, with the specific goal of measuring survival free of dementia and disability.7PubMed. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale Its results, expected in the next couple of years, should help settle the primary prevention question more definitively.
A Real-World Look at Absolute Risk Reduction
Relative risk reductions sound impressive, but what matters to an individual patient is the absolute reduction: how many fewer events per hundred people over a given number of years. A target trial emulation study using real-world data found that for adults aged 75 to 84, starting a statin for primary prevention was associated with an absolute reduction in cardiovascular disease of about 1.2 percentage points over five years. For adults 85 and older, the absolute reduction was larger, around 4.4 percentage points. Neither age group showed a significantly increased risk of muscle problems or liver dysfunction.8Annals of Internal Medicine. Benefits and Risks Associated With Statin Therapy for Primary Prevention in Old and Very Old Adults A modeling study estimated that treating all adults aged 75 to 94 would prevent about 105,000 heart attacks and 68,000 coronary deaths in the United States, at a cost that falls within the range generally considered acceptable for a healthcare intervention.9Annals of Internal Medicine. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States
These numbers help frame the decision. A 1.2 percentage point absolute reduction over five years means you would need to treat roughly 83 people for five years to prevent one cardiovascular event in the 75-to-84 group. For people 85 and older, the number needed to treat is much smaller. Whether that tradeoff is worth it depends on what the person values and what other health concerns they face.
Should You Stop a Statin You’re Already Taking?
A slightly different question from “should I start?” is “should I stop?” Many 80-year-olds have been on statins for years or decades. The deprescribing evidence here is worth knowing, because stopping is not the same as never starting.
A Danish study of older adults who stopped their statin found that discontinuation was associated with roughly one extra major cardiovascular event per 112 person-years in primary prevention patients, and one per 77 person-years in secondary prevention patients.10JAMA Network Open. Statin Discontinuation and Cardiovascular Events Among Older People in Denmark Another study of older patients on multiple medications found that those who stopped statins had a higher risk of hospitalization for heart failure, cardiovascular events overall, and death from any cause.11JAMA Network Open. Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy
There is a meaningful exception, though. A randomized trial of patients with an estimated life expectancy of one month to one year found that stopping statins did not increase cardiovascular events or shorten survival. The group that stopped actually reported better quality of life.12PubMed Central. Deprescribing Cardiovascular Medications in Older Adults Living with Frailty So for people who are severely frail or approaching end of life, stopping makes sense. For those who are still relatively healthy and active, the data suggest caution about simply discontinuing a long-running statin.
The Cholesterol Paradox in Old Age
One of the more confusing things about cholesterol in the elderly is that the relationship between LDL cholesterol and mortality appears to weaken or even reverse at advanced ages. A systematic review found that in the majority of elderly cohorts studied, lower LDL was actually associated with higher all-cause mortality, not lower.13PubMed. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review A study of nonagenarians in a Sardinian longevity “Blue Zone” found that those with LDL above 130 mg/dL survived significantly longer than those with lower levels.14PubMed Central. The Cholesterol Paradox in Long-Livers from a Sardinia Longevity Hot Spot (Blue Zone)
This does not mean high cholesterol is protective or that statins are harmful. The most likely explanation is what epidemiologists call reverse causation and the “sick old” effect: people who are already declining from cancer, chronic illness, or frailty tend to have falling cholesterol levels. Those who are robust enough to maintain higher cholesterol are healthier for reasons that have nothing to do with cholesterol itself. It does, however, underscore why applying the standard middle-aged cholesterol logic directly to an 80-year-old is not straightforward.
What About the Brain?
Concerns about statins and cognitive decline are common among older adults, and the evidence here is more reassuring than many people expect. A large meta-analysis found that statin use was associated with a roughly 14% reduction in overall dementia risk and an 18% reduction in Alzheimer’s disease specifically.15PubMed Central. Statin use and dementia risk: A systematic review and updated meta-analysis A secondary analysis from the Ginkgo Evaluation of Memory Study found that statin use in people without cognitive impairment at the start of the study was associated with reduced risk of dementia and Alzheimer’s, with lipophilic statins possibly more protective.16PubMed Central. Statins, Risk of Dementia and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study (GEMS)
There is a nuance worth noting. One study found that statin users initially scored slightly lower on cognitive tests, but this appeared to be driven by the fact that statins lower LDL and certain inflammatory markers, which themselves correlate with cognitive scores at a single point in time. When the same participants were tested eight years later, statin use had no association with cognitive performance.17PubMed Central. The Effects of Statins on Cognitive Performance Are Mediated by Low-Density Lipoprotein, C-Reactive Protein, and Blood Glucose Concentrations In other words, statins do not appear to cause cognitive decline, and may actually reduce the risk of dementia, though the protection was not seen in people who already had mild cognitive impairment.
Muscle Problems and Fall Risk
Muscle complaints are the most commonly cited reason older adults stop taking statins, and it’s the side effect people worry about most. The reality is more complicated than the popular narrative suggests. A Japanese community-based study of middle-aged and older adults found that long-term statin use was not associated with an increased risk of sarcopenia, reduced muscle mass, diminished muscle strength, or impaired physical performance, and these findings held up across age and sex subgroups.18PubMed Central. Risk of Sarcopenia Following Long‐Term Statin Use in Community‐Dwelling Middle‐Aged and Older Adults in Japan
However, an older study of community-dwelling older adults found that statin users had worse muscle performance and higher fall risk without a measurable decrease in muscle mass, and these effects appeared to be reversible when statins were stopped.19PubMed. Statin therapy, muscle function and falls risk in community-dwelling older adults The picture that emerges is that true muscle wasting from statins is rare, but some people do experience functional muscle symptoms like weakness or aching that can affect daily life, especially if they are already frail. At 80, where a fall can be life-threatening, this deserves serious consideration even if the absolute risk is low.
Drug Interactions at 80
Most 80-year-olds take multiple medications, and statin drug interactions become a practical concern. Many statins are processed by the liver enzyme CYP3A4. When another drug that inhibits this enzyme is added to the mix, statin levels in the blood can rise, increasing the risk of serious muscle damage. One of the most common interactions involves simvastatin taken alongside the blood pressure drug amlodipine; the combination can substantially increase simvastatin levels, and case reports of serious rhabdomyolysis in older adults have been documented. Guidelines recommend limiting simvastatin to 20 mg or less when taken with amlodipine.20PubMed Central. Polypharmacy and Potential Drug–Drug Interactions in Home-Dwelling Older People – A Cross-Sectional Study The heart rhythm drug amiodarone with statins, and atorvastatin with certain calcium channel blockers like verapamil or diltiazem, are also flagged as frequent interaction pairs in hospitalized elderly patients.21European Journal of Internal Medicine. Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients
This is not a reason to avoid statins altogether, but it is a reason to make sure your prescriber reviews your full medication list and chooses a statin less prone to interactions. Pravastatin, rosuvastatin, and pitavastatin are processed differently and are generally safer in polypharmacy situations.
Using Calcium Scores to Decide
One increasingly popular way to cut through the uncertainty is the coronary artery calcium (CAC) score, measured by a quick CT scan. The CAC score reflects how much calcium has built up in the coronary arteries and is a direct marker of existing atherosclerosis, even when a person has never had symptoms. In older adults, where traditional risk calculators lose some of their accuracy, the CAC score provides better discrimination between people at higher and lower risk for heart disease than age alone does.22JAMA Cardiology. Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies
For people in the ambiguous risk range, a CAC test can reclassify risk upward or downward in about half of cases, meaningfully changing whether a statin looks worthwhile.23Mayo Clinic Proceedings. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention A score of zero is particularly useful because it identifies people at very low risk who are unlikely to benefit and could reasonably skip or stop statin therapy.12PubMed Central. Deprescribing Cardiovascular Medications in Older Adults Living with Frailty A high score, on the other hand, suggests subclinical disease is already present and the case for treatment is stronger. For an 80-year-old on the fence, this is one of the more practical tools available.
Combination Therapy as a Gentler Alternative
High-intensity statin therapy brings more side-effect concerns, and older adults are more likely to stop taking the medication because of them. One alternative gaining evidence is combining a moderate-dose statin with ezetimibe, a drug that blocks cholesterol absorption in the gut. A trial of patients aged 75 and older found that combining moderate-intensity statins with ezetimibe achieved the same cardiovascular outcomes as high-intensity statin monotherapy, with notably fewer drug discontinuations due to intolerability. Among those 75 and older, only about 2% on combination therapy stopped or reduced their dose for side effects, compared to about 7% on high-intensity statin alone.24Journal of the American College of Cardiology. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis
For secondary prevention after a heart attack, the benefit of adding ezetimibe appears to actually grow with age. In one large trial, patients 75 and older receiving simvastatin plus ezetimibe had an absolute 8.7 percentage-point reduction in major cardiovascular events over seven years compared to simvastatin alone. The number needed to treat to prevent one event was just 11, compared to 125 for patients under 75.25JAMA Cardiology. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older A more recent study confirmed that combination therapy achieved slightly better non-HDL cholesterol reduction and was associated with substantially fewer muscle symptoms compared to high-dose statin alone.26PubMed Central. Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients
New-Onset Diabetes From Statins
Statins modestly increase the risk of developing diabetes, and this risk is higher with more potent doses. A large meta-analysis of individual participant data from randomized trials found that low-to-moderate intensity statin therapy increased new diabetes by about 10%, while high-intensity therapy increased it by about 36%.27The Lancet. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from large randomised controlled trials For anyone with prediabetes, obesity, or other metabolic risk factors, high-intensity statins like atorvastatin and rosuvastatin carry the greatest concern. Pravastatin and pitavastatin appear to have less metabolic impact.28PubMed Central. Statin Induced New-onset Diabetes Mellitus – A Narrative Review
Interestingly, though, one study specifically looking at elderly patients on statins for primary prevention found that the risk of new-onset diabetes was increased in younger adults but not in the older group.29PubMed. Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality This may mean that by 80, the metabolic susceptibility either has already manifested or that the baseline risk profile is different enough that the statin-diabetes link is less clinically relevant. Still, for an 80-year-old with borderline blood sugar, it’s worth discussing which statin to choose.
Why Guidelines Disagree
If you compare the major North American and European cholesterol guidelines released in recent years, you’ll find they give markedly different advice about statins for primary prevention in older adults. Some recommend statin therapy for high-risk adults regardless of age; others decline to make a recommendation above age 75 due to insufficient evidence; still others suggest shared decision-making as a catch-all when the data are thin.30Journal of the American College of Cardiology. Primary Prevention With Statins in the Elderly A critical review of seven such guidelines found that the disagreement stems directly from the gaps in the literature: too few randomized trials have included very old adults, and the ones that exist often cap enrollment at 75 or 80.31PubMed Central. Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines
This leaves clinicians and patients in the uncomfortable position of having to make a decision without definitive guidance, which is exactly why expert panels increasingly emphasize shared decision-making for this age group. Canadian deprescribing guidelines explicitly note that decisions should consider function, mobility, cognition, frailty, social circumstances, life expectancy, pill burden, and personal values.32Canadian Family Physician. Deprescribing statins for adults 65 years of age and older
How Sex Affects the Equation
Women over 80 face a distinct set of issues with statin therapy. They are less frequently prescribed statins in the first place, and when they are, they tend to receive lower doses, even after a heart attack. They are also more likely to stop taking statins because of side effects. Part of this is physiological: women have a lower kidney filtration rate, higher body fat percentage, and faster statin metabolism, all of which can alter how the drug behaves in their bodies.33PubMed Central. Cardiovascular Risk and Statin Therapy Considerations in Women Part of it is a problem of evidence: women, especially older women, have been underrepresented in statin trials, so the confidence interval around any recommendation is wider. An older woman considering a statin deserves a conversation that accounts for these differences rather than a one-size-fits-all prescription.
What Statins Do Inside Aging Arteries
The relationship between statins and arterial calcification is counterintuitive. Statins can actually increase the amount of calcium deposited in artery walls, which sounds alarming until you understand the difference between stable and unstable plaque. Unstable plaque is the kind that ruptures and causes heart attacks. Statins appear to promote a shift from soft, rupture-prone plaque toward dense, stable calcification that is less likely to break apart.34PubMed Central. The Complex Mechanisms and the Potential Effects of Statins on Vascular Calcification: A Narrative Review In animal models, pravastatin increased the number of tiny calcium deposits while reducing markers of active, dangerous calcification, consistent with a stabilizing effect on existing disease.35PubMed Central. Statin effects on vascular calcification: Microarchitectural changes in aortic calcium deposits in aged hyperlipidemic mice This helps explain why CAC scores sometimes rise on statin therapy without an increase in events, and why a rising calcium score while on a statin is not necessarily bad news.